{
    "doi": "https://doi.org/10.1182/blood.V108.11.5345.5345",
    "article_title": "Transplant-Associated Thrombotic Microangiopathy (TAM): A Study Comparing Hemopoietic Stem Cells (HSCT) and Solid Organ (SO) Transplant (TX) Recipients. ",
    "article_date": "November 16, 2006",
    "session_type": "Abstracts Not Selected for Presentation",
    "abstract_text": "TAM is associated with a poor prognosis and outcome. Reported incidence varies from 0.5 to 76%. Risk factors (RF) include use of calcineurin inhibitors(CNI), infections, conditioning chemotherapy regimen and graft versus host disease. Although treatment (TMT) modalities such as inmunosuppressive drugs withdrawal, plasma exchange or infusion are used to improve the outcome, optimal therapeutic strategies are not clearly defined. OBJECTIVE: To compare the incidence, RF and outcome of patients (pts) with TAM after HSCT and SOTX. PATIENTS AND METHODS: In 1172 consecutive pts transplanted between february 2000 and june 2006, 22 TAM episodes were diagnosed. TAM Dg was defined as evidence of hemolysis and schistocytes in blood smear. Thrombocytopenia (TCP), neurological (NRL) or renal (RNL) dysfunction were not included in the diagnostic criteria. RESULTS: MAT incidence was 5,41% (11/203) in HSCT and 1,13% (11/969) in SOTX pts (p<0,0006). Median follow up of surviving pts was 1144 days (range: 281\u20132432). Overall mortality was 36,36% (8/22), 4/11 HSCT and 4/11 SOTX.  . HSCT m . HSCT r . SOTX m . SOTX r . m: media r: range Age (years) 23,6 7\u201342 54 31\u201369 Sex (male) (%) 63,6  54,5  Time to Dg (days) 68,2 12\u2013236 111,4 4\u20131097 TCP at Dg (%) 81,8  100  NRL at Dg (%) 18,2  40  RNL at Dg (%) 18,2  63,6  Hematocrite at Dg/post TMT(%) 26,9/34,3 20\u201335/25\u201348 18,5/32,8 18\u201328/29\u201337 LDH at Dg/post TMT 1186,4/946,4 607\u20132247/548\u20131629 1325,7/522 639\u20133960/295\u2013630 Platelets at Dg/post TMT (\u00d710 3 /ml) 66,9/158 5\u201330/20\u2013380 48/139 15\u201390/5\u2013280 Urea/creatinine at Dg 66/1,2 17\u201395/0,6\u20132,3 124,8/3,4 41\u2013190/0,9\u20136,5 Total Bilirrubin/Indirect Bilirrubin at Dg 6,2/2,3 0,7\u201314/0,4\u20135,5 3,2/1,9 0,4\u201313/0,2\u20137,7 Cyclosporine/FK at Dg (%) 81,8/18,2  9,1/90  TMT response (%) 72,7  80  Days to last evaluation (all/survival pts) 784,8/978,3 26\u20131584/281\u20131584 850,6/1310,6 26\u20132342/374\u20132237 Days to death since TX 391 26\u2013908 58,7 26\u201396 Days to death since MAT Dg 361 6\u2013862 12,8 7\u201320 . HSCT m . HSCT r . SOTX m . SOTX r . m: media r: range Age (years) 23,6 7\u201342 54 31\u201369 Sex (male) (%) 63,6  54,5  Time to Dg (days) 68,2 12\u2013236 111,4 4\u20131097 TCP at Dg (%) 81,8  100  NRL at Dg (%) 18,2  40  RNL at Dg (%) 18,2  63,6  Hematocrite at Dg/post TMT(%) 26,9/34,3 20\u201335/25\u201348 18,5/32,8 18\u201328/29\u201337 LDH at Dg/post TMT 1186,4/946,4 607\u20132247/548\u20131629 1325,7/522 639\u20133960/295\u2013630 Platelets at Dg/post TMT (\u00d710 3 /ml) 66,9/158 5\u201330/20\u2013380 48/139 15\u201390/5\u2013280 Urea/creatinine at Dg 66/1,2 17\u201395/0,6\u20132,3 124,8/3,4 41\u2013190/0,9\u20136,5 Total Bilirrubin/Indirect Bilirrubin at Dg 6,2/2,3 0,7\u201314/0,4\u20135,5 3,2/1,9 0,4\u201313/0,2\u20137,7 Cyclosporine/FK at Dg (%) 81,8/18,2  9,1/90  TMT response (%) 72,7  80  Days to last evaluation (all/survival pts) 784,8/978,3 26\u20131584/281\u20131584 850,6/1310,6 26\u20132342/374\u20132237 Days to death since TX 391 26\u2013908 58,7 26\u201396 Days to death since MAT Dg 361 6\u2013862 12,8 7\u201320 View Large CONCLUSIONS: In our experience TAM was an uncommon complication and its incidence was higher during the first 3 months after transplantation. It was more frequent among HSCT recipients. At Dg all TAM pts were receiving CNI as part of the immunosuppressive protocol. Drug withdrawal improved laboratory results and pt outcome in both groups. NRL and renal symptoms were more frequently seen in SOTX. Survival after TAM Dg in SOTX was shorter compared to HSCT recipients. Both groups showed similar mortality rate (36,36%).",
    "topics": [
        "hematopoietic stem cell transplantation",
        "stem cells",
        "thrombotic microangiopathies",
        "transplantation",
        "brachial plexus neuritis",
        "blood smear",
        "calcineurin inhibitors",
        "chemotherapy regimen",
        "creatinine",
        "cyclosporine"
    ],
    "author_names": [
        "Dolores Puente, MD",
        "Maria Tabares, MD",
        "Alejandro Requejo, MD",
        "Colorio Cecilia, MD",
        "Nicolas Bonini, MD",
        "Andrea Rossi, MD",
        "Viviana Listello, MD",
        "Vera Milovic, MD",
        "Gregorio Jaimovich, MD",
        "Gonzalo Pombo, MD",
        "Leonardo Feldman, MD"
    ],
    "author_dict_list": [
        {
            "author_name": "Dolores Puente, MD",
            "author_affiliations": [
                "Hematology, Fundacion Favaloro, Buenos Aires, Argentina"
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Maria Tabares, MD",
            "author_affiliations": [
                "Hematology, Fundacion Favaloro, Buenos Aires, Argentina"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alejandro Requejo, MD",
            "author_affiliations": [
                "Bone Marrow Transplant, CEHT, Buenos Aires, Argentina"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Colorio Cecilia, MD",
            "author_affiliations": [
                "Hematology, Fundacion Favaloro, Buenos Aires, Argentina"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Nicolas Bonini, MD",
            "author_affiliations": [
                "Bone Marrow Transplant, CEHT, Buenos Aires, Argentina"
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Andrea Rossi, MD",
            "author_affiliations": [
                "Hematology, Fundacion Favaloro, Buenos Aires, Argentina"
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Viviana Listello, MD",
            "author_affiliations": [
                "Bone Marrow Transplant, CEHT, Buenos Aires, Argentina"
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Vera Milovic, MD",
            "author_affiliations": [
                "Bone Marrow Transplant, CEHT, Buenos Aires, Argentina"
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Gregorio Jaimovich, MD",
            "author_affiliations": [
                "Bone Marrow Transplant, CEHT, Buenos Aires, Argentina"
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Gonzalo Pombo, MD",
            "author_affiliations": [
                "Hematology, Fundacion Favaloro, Buenos Aires, Argentina"
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Leonardo Feldman, MD",
            "author_affiliations": [
                "Bone Marrow Transplant, CEHT, Buenos Aires, Argentina"
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-02T06:41:16",
    "is_scraped": "1"
}